Search

Displaying results 6591 - 6600 of 8171 in total
  1. Drug

    Neladalkib

    go.drugbank.com/drugs/DB21712
    Investigational

    Neladalkib has a monoisotopic molecular weight of 452.15 Da.

    Synonyms: an orally bioavailable ALK inhibitor (a macrocyclic compound containing nitrogen heterocycles)
  2. Drug

    Xiliertinib

    go.drugbank.com/drugs/DB21453
    Investigational

    Xiliertinib has a monoisotopic molecular weight of 442.21 Da.

  3. Drug

    Paltimatrectinib

    go.drugbank.com/drugs/DB21588
    Investigational

    Paltimatrectinib has a monoisotopic molecular weight of 434.13 Da.

  4. Drug

    FT516

    go.drugbank.com/drugs/DB15732
    Investigational

    FT516 is an investigational and engineered off-the-shelf natural killer (NK) cell therapy originating from induced pluripotent stem cells (iPSC). … This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding ability to tumor-targeting antibodies, and is resistant to downregulation.

  5. Drug

    GEM-231

    go.drugbank.com/drugs/DB05798
    Investigational

    Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells.

  6. Drug

    Bafilomycin A1

    go.drugbank.com/drugs/DB06733
    Experimental

    This is a useful tool as it can prevent the re-acidification of synaptic vesicles once they have undergone exocytosis.

  7. Drug

    MC-1

    go.drugbank.com/drugs/DB05315
    Experimental

    Medicure's MC-1 drug is a cardio-protectant, designed to reduce the damage to the heart when arteries are blocked and when they are subsequently reopened after bypass surgery.

  8. Drug

    Iptacopan

    go.drugbank.com/drugs/DB16200
    ApprovedInvestigational

    Due to this mutation, all progeny erythrocytes will lack the glycosyl phosphatidylinositol–anchored proteins that normally anchor 2 membrane proteins, CD55 and CD59, that protect blood cells against the

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Substrates
  9. Drug

    Droxidopa

    go.drugbank.com/drugs/DB06262
    ApprovedInvestigational

    The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension.

  10. Drug

    AUTO3

    go.drugbank.com/drugs/DB17364
    Investigational

    It is an investigational chimeric antigen receptor (CAR) T cell treatment targeting CD19 and CD22.